Integral Diagnostics (IDX) H1 2025 earnings summary

Executive summary

• Completed merger with Capitol Health on 20 December 2024, expanding to 150 clinics and over 350 radiologists, targeting at least AUD 10 million in annual pre-tax net cost synergies, most realized in the first year.

• Standalone revenue grew 7.8% to $249.4m, operating EBITDA up 8.2% to $46.8m, and operating NPAT up 31.9% to $9.8m year-over-year.

• Served over 600,000 patients and performed 1.3 million exams in the half, with high Net Promoter Scores in Australia (+83) and New Zealand (+79).

• Declared a fully franked interim dividend of 2.5 cents per share, with a payout ratio of 106.1% of operating NPAT on a merged basis.

• Integration program underway to unite teams, with structured engagement and site visits.

Financial highlights

• Total revenue and other income rose to $253.4m from $231.6m year-over-year, with free cash flow up 22.7% to $29.4m and conversion at 88.8%.

• Operating EBITDA margin slightly expanded to 18.8% (vs. 18.7% prior year), with operating diluted EPS up 14.2% to 3.6 cents per share.

• Net debt increased to $298.7m due to the Capitol acquisition, but net debt/EBITDA improved to 2.8x (2.6x including synergies), down from 3.0x.

• Growth CapEx of AUD 14.8 million, total CapEx AUD 26.9 million, with replacement CapEx of $12.1m.

• Net loss for the half-year was $(0.4)m, a significant improvement from $(66.8)m in the prior year period.

Outlook and guidance

• Positioned to benefit from MRI deregulation and the National Lung Cancer Screening Program starting July 2025.

• FY25 replacement and growth CapEx expected at AUD 60-65 million, including AUD 20 million for Capitol.

• Focus on organic growth, teleradiology, digital/AI, and post-merger integration.

• Expecting margin improvement from operational initiatives, merger synergies, and regulatory changes.

• Industry fundamentals remain strong, supported by demographic and technological trends.